Lundbeck Q3 2019 Financial Results

Significant reduction in monthly migraine days (MMDs) with eptinezumab at both 100mg and 300 mg Eptinezumab has shown high response rates, especially in adult patients experiencing frequent, chronic migraine ~60% of patients had ≥50% PROMISE-1 (Change from baseline in MMDs) 0 -2 PROMISE-2 (Change from baseline in MMDS) 17 * * reduction in migraine days ~40% of patients had ≥75% reduction in migraine days Patients that experienced no migraines for at least half of the study period (≥3 mth): 100mg: 14.0% 300mg: 19.1% *Placebo: 4.9% -3,2 -4 -6 -5,6 -6,2 -3,8 -8 -3,9 -7,7 キ -8,2 -8,2 -4,3 t -8,8 -4,5 -4,8 -10 Infusion 1 (Months 1-3) Infusion 1 (Months 1-3) Infusion 2 (Months 4-6) Infusion 2 (Months 4-6) Eptinezumab 100mg Placebo Eptinezumab 300mg Eptinezumab 100mg Eptinezumab 300mg Placebo *p=0.0182; tp=0.0001; #p<0.0001 vs placebo. Months 4-6 were not included in the prespecified statistical algorithms. Lundbeck

View entire presentation